3Q 2025 Total revenue grew 25% year-over-year to $59.4 million driven by 42% year-over-year growth in Payor revenue 3Q 2025 Net income of $3.3 million and adjusted EBITDA¹ of $5.0 million 3Q 2025 Share repurchases of $8.8 million NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Talkspace, Inc. (“Talkspace” or the “Company”) (NASDAQ: TALK), today reported third quarter 2025 financial results. Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2025 2024 2025<td style="text-align: center ; vertic ...

Kinetic customers can now get an enhanced internet experience powered by 100% fiber, and eero Wi-Fi 7 to deliver fast, reliable whole-home connectivityThis relationship underscores Kinetic’s plan to deliver innovative, future-proof, whole-home connectivity across an 18-state footprintNew ‘Kinetic Promise’ nears 1 million certified whole-home Wi-Fi installations across 18 states CHARLOTTE, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kinetic, a leading residential and business fiber internet provider, announced t ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- ABM (NYSE: ABM), a leading provider of facility, engineering, and infrastructure solutions, today announced the appointment of Barry Hytinen to its Board of Directors. Mr. Hytinen currently serves as Executive Vice President and Chief Financial Officer of Iron Mountain Incorporated (NYSE: IRM), a global leader in information management services. He has more than two decades of experience in corporate finance, strategic transformation, and operational leadership a ...

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the presentation of new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer (SITC) Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic sites after ...

Core Insights - The majority of Americans feel unprepared for grid instability, electricity outages, and extreme weather, leading to increased demand for home battery storage and solar solutions from Sunrun [1][3] Group 1: Rising Demand and Grid Strain - A national survey indicates that homeowners are losing confidence in traditional utilities' ability to meet rising energy needs, driven by factors such as AI and data centers [2][4] - 80% of respondents worry that data centers will increase their electricity costs, and 68% are concerned that their utility provider cannot keep up with growing energy demand [9] Group 2: Impact of Outages - Nearly 87% of Americans have experienced real consequences from power outages, including spoiled food and interrupted access to medical equipment [6] - 81% reported at least one power outage in the past year, with 60% facing up to three outages [9] Group 3: Desire for Energy Independence - Homeowners increasingly view distributed energy resources as a solution for personal resilience and public benefit, with 62% considering home battery storage systems [7][10] - 91% believe that home solar and batteries strengthen the grid, and 92% are willing to share excess energy with neighbors during peak demand [10] Group 4: Sunrun's Role and Solutions - Sunrun's home storage and solar systems are positioned as scalable solutions to stabilize the grid and provide families with more control over their energy [8] - The company emphasizes that every home with storage and solar contributes to America's energy future, lowering costs and enhancing national security [9]

Kojamo plc Stock Exchange Release, 30 October 2025 at 2.00 p.m. EET Kojamo plc’s Interim Report 1 January–30 September 2025 Occupancy rate improved, total revenue and net rental income increased This is a summary of the January–September Interim Report, which is in its entirety attached to this release and can be downloaded from the company’s website at www.kojamo.fi/investors. Unless otherwise stated, the comparison figures in brackets refer to the corresponding period of the previous year. The figures in ...

COOTAMUNDRA, Australia, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited (the “Company”) (NASDAQ: COOT), a manufacturer and seller of sustainable edible oils to customers globally, today announced it has received written notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). This confirmation was followed by Nasdaq’s approval of the Company’s application to transfe ...

Advanced Drones to Enhance Training Against Multinational Forces at Joint Multinational Readiness Center WICHITA, Kan., Oct. 30, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (dba, EagleNXT) (the “Company” or “EagleNXT”) (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, is proud to announce the sale of three eBee VISION drones to the U.S. Army’s 1st Battalion, 4th Infantry Regiment (1-4 IN), stationed at the Joint Multinational Readiness Center (JMRC) in Hohenfels, Germ ...

MATTOON, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- First Mid Bancshares, Inc. (NASDAQ: FMBH) (the “Company”) today announced its financial results for the quarter ended September 30, 2025. Highlights Quarterly net income of $22.5 million, or $0.94 diluted EPSAdjusted quarterly net income* of $23.3 million, or $0.97 diluted EPSNet interest margin tax equivalent* expands to 3.80%, quarterly increase of 8 basis points, helping drive the sixth consecutive quarter of growth in net interest incomeTotal loans of $5. ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has been invited to present a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly ...